Stent

United States Cardiovascular Devices Market, Size, Share, Forecast 2024-2030 Featuring Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Cardinal Health, Medtronic, GE, J&J, & Siemens - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Health, Medical Devices, Cardiology, Hospital, Cardiac catheterization, Disease, American Heart Association, Stent, Cardiovascular disease, Coronary artery disease, Prevalence, Biotechnology, CVD, ECG, Incidence, Diabetes, Electrocardiography, Public, Research, Mortality, Insight, Death, Risk, Arrhythmia, Diagnosis, Heart failure, CAD, Medical device

Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.

Key Points: 
  • Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.
  • Technology is pivotal in employing growth in the United States cardiovascular devices market.
  • Numerous market players actively enforce strategic tasks, propelling an increase in the United States cardiovascular devices market.
  • In the United States cardiovascular devices market, diagnostics and monitoring devices have a significant presence
    The United States cardiovascular device market is broken up by device type into Diagnostics and Monitoring Devices and Therapeutic and Surgical Devices.

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Blood pressure, CRT, Investigational device exemption, HOPE, Patient, Inflammation, Stroke, Gold, Restenosis, ISR, Medtronic, Beat (music), Trial of the century, Virtue, Sirolimus, Stent, Safety, Pharmacokinetics, SAB, Hypertension, Molecular mass, Food, Medical device

A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure.

Key Points: 
  • A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure.
  • The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.
  • Specifically, the presented PK data showed that:
    Molecular weight of Sostenocel remained unchanged prior to elimination, showing no evidence of in-vivo degradation.
  • AVIM therapy demonstrated:
    Consistent favorable hemodynamic effects using both conduction system, as well as traditional right ventricular lead placements.

Ropes & Gray Expands its Antitrust Team with Arrival of Jackie Grise

Retrieved on: 
Monday, March 18, 2024
Culture, Head, Amazon, Environment, Horizon Therapeutics, Ropes & Gray, Arena Pharmaceuticals, Sale, Acquisition, Woman, Intersect ENT, Lawyer, Therapy, Mastercard, Stent, PI, Amgen, Intersection, FTC

Jackie, a Chambers-ranked practitioner, brings more than 25 years of antitrust experience—and a strong understanding of government antitrust enforcement priorities—to Ropes & Gray's global client base.

Key Points: 
  • Jackie, a Chambers-ranked practitioner, brings more than 25 years of antitrust experience—and a strong understanding of government antitrust enforcement priorities—to Ropes & Gray's global client base.
  • She has successfully guided antitrust reviews in headline deals in which U.S. antitrust enforcers have issued "second requests."
  • Jackie expands Ropes & Gray's award-winning antitrust practice, which Chambers notes "offers top-flight representation across the full spectrum of antitrust matters," across industries where Ropes & Gray is a giant – private equity, asset management, health care, life sciences, and technology, among other key areas.
  • I am excited and proud to join the already elite, deep bench of antitrust lawyers on the team," said Jackie.

Baylis Medical Technologies Announces Launch of PowerWire® Pro RF Guidewire, Enhancing Access to Care for Patients with Occluded Venous Stents

Retrieved on: 
Monday, March 18, 2024
Patient, Stent, Family, Health, History, Radiology, RF, Medical imaging

The PowerWire® Pro RF Guidewire has been thoughtfully designed to address this challenge by employing radiofrequency technology to cross totally occluded stents in peripheral vessels.

Key Points: 
  • The PowerWire® Pro RF Guidewire has been thoughtfully designed to address this challenge by employing radiofrequency technology to cross totally occluded stents in peripheral vessels.
  • The addition of the PowerWire® Pro RF Guidewire to Baylis Medical Technologies' portfolio of radiofrequency wires expands its clinical solutions in radiology and vascular surgery.
  • Frank Baylis, Executive Chairman of Baylis Medical Technologies, expressed enthusiasm about the PowerWire® Pro RF Guidewire's potential impact, stating, "We are very excited to announce new additions to our family of PowerWire® RF Guidewires.
  • The PowerWire® Pro RF Guidewire broadens the doctors' capabilities in treating such occlusions, where traditional methods have previously fallen short."

OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share

Retrieved on: 
Thursday, March 7, 2024
Stent, Acquisition, MDR, Education, Cardiac catheterization, Sapphire, FDA, Marketing, Quality of life, Medical device regulation, PTCA, Physician, Growth, OrbusNeich, Medicare, PMDA, PTA, Abbott Laboratories, Percutaneous coronary intervention, Patient, Clinical trial, Knowledge, NMPA, Laboratory, Research, PCI

-- Revenue hit record high at US$153.9 million, up 12.5% year-on-year

Key Points: 
  • -- Revenue hit record high at US$153.9 million, up 12.5% year-on-year
    -- Revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year, respectively.
  • In particular, revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year to US$115.4 million and US$14.7 million, respectively.
  • As at December 31, 2023, the Group was in a strong financial position with cash and bank balances amounting to US$255.8 million (2022: US$229.1 million).
  • Having considered future capital requirements, the Board has proposed a final dividend of HK10 cents per share in cash, as a token of appreciation for the continuous support of shareholders.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024
CMS, Pi, Growth, Radiology, IDE, State university system, CAD, Buffalo, PMA, MDR, TEL, Medical device regulation, Health, Stroke, CAS, TCAR, EPS, EFS, Thomas Jefferson University, European, Carotid artery stenosis, Myocardial infarction, CE marking, Vascular disease, Thrombectomy, Clinical trial, Medicaid, NPS, CEA, Good Samaritan Hospital, Stenosis, Risk, Blood vessel, Medicare, Death, Stent, Patient, Medicine, NSPR, Pharmaceutical industry

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 and Recent Developments:
    Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
  • Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
  • Financial Results for the Fourth Quarter Ended December 31, 2023
    For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  • Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.

Global Pediatric Interventional Cardiology Market Forecast 2024-2030: PIC Market Forecast for 6.36% CAGR Between 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
General Health, Health, Cardiology, Heart, Incidence, Procedure, Catheter, Birth defect, Investment, Physician, Moyamoya disease, Congenital heart defect, Projection, VSD, Angioplasty, Prevalence, CHD, Coronary thrombosis, Atherectomy, Patient, Stent, Ventricular septal defect, CDC, Catheter ablation, Research, Medical imaging

The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.

Key Points: 
  • The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.
  • The pediatric interventional cardiology market proportion is expanding swiftly, driven by the rising prevalence of cardiac disorders in children and technological advancements.
  • The Stents segment is anticipated to dominate the global pediatric interventional cardiology market throughout the forecast period.
  • The comprehensive infrastructure of hospitals, coupled with their ability to provide diverse pediatric cardiology services, positions them as key contributors to the growth and development of the Pediatric Interventional Cardiology market.

Lung Stent Market to reach $333.8 million, globally, by 2030 at 7.1% CAGR: Coherent Market Insights

Retrieved on: 
Tuesday, February 20, 2024
Boston Scientific, Cook Group, Research, Neoplasm, Traction, Inflammation, Hospital, Quality of life, Stainless steel, Growth, Airway obstruction, Pneumonia, Risk, Chronic obstructive pulmonary disease, Prevalence, Metal, Stent, Patient, Lung cancer, Medtronic, COPD, Uranium mining

The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.

Key Points: 
  • The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.
  • Metal lung stents are expected to dominate the lung stent market in terms of material type.
  • The increasing prevalence of lung diseases, such as lung cancer and pneumonia, is driving the demand for metal lung stents.
  • Tracheobronchial stents and metal lung stents are projected to be the key market opportunities, while North America is expected to dominate the market.

Laura Davis Joins VisionAir Solutions as Executive Director of Education

Retrieved on: 
Wednesday, February 14, 2024
Physician, FDA, Bachelor of Science, University of Michigan, Pulmonology, Business development, Lead, Dynasplint Systems, Stent, Patient, Western Michigan University, Anatomy, Disease, Software

CLEVELAND, Feb. 14, 2024 /PRNewswire/ -- VisionAir Solutions, a Cleveland, Ohio-based company that creates patient-specific airway stents announced that Laura Davis has joined its team as Executive Director of Education.

Key Points: 
  • Business development and sales leader Laura Davis joins VisionAir Solutions team as Executive Director of Education.
  • CLEVELAND, Feb. 14, 2024 /PRNewswire/ -- VisionAir Solutions, a Cleveland, Ohio-based company that creates patient-specific airway stents announced that Laura Davis has joined its team as Executive Director of Education.
  • Business development and sales leader Laura Davis joins VisionAir Solutions team as Executive Director of Education.
  • Laura joins VisionAir from an impressive background as a sales leader and education consultant.

Medical Polymers Market Size to Grow USD 21320 Million by 2029 at a CAGR of 3.1% | Valuates Reports

Retrieved on: 
Wednesday, February 7, 2024
Polymer, Stent, Regenerative medicine, Conditional sentence, Biomaterial, Catheter, Ageing, Packaging and labeling, DSM, Polyethylene, PVC, Incidence, Tissue engineering, Biodegradable plastic, Polyvinyl chloride, Medical device, Diabetes, Administration, Risk, Cancer, Equipment, BASF

BANGALORE, India , Feb. 7, 2024 /PRNewswire/ -- Medical Polymers Market is Segmented by Type (Medical Resins and Fibers, Medical Elastomers, Biodegradable Plastics), by Application (Medical Devices and Equipment, Medical Packaging).

Key Points: 
  • BANGALORE, India , Feb. 7, 2024 /PRNewswire/ -- Medical Polymers Market is Segmented by Type (Medical Resins and Fibers, Medical Elastomers, Biodegradable Plastics), by Application (Medical Devices and Equipment, Medical Packaging).
  • The growing need for biocompatible materials in the healthcare industry is driving the expansion of the medical polymers market.
  • Biocompatible polymers, including polyethylene, polypropylene , and polyvinyl chloride (PVC) , find widespread application in drug delivery systems, implants, and medical devices.
  • https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-18T15867...
    The top companies in the worldwide market for medical polymers include BASF SE, Bayer, Celanese, DSM, Du Pont, and others.